{
    "clinical_study": {
        "@rank": "112891", 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety and efficacy of TLK199 in patients with\n      myelodysplastic syndrome (MDS)."
        }, 
        "brief_title": "Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome", 
        "completion_date": {
            "#text": "May 2007", 
            "@type": "Actual"
        }, 
        "condition": "Myelodysplastic Syndromes", 
        "condition_browse": {
            "mesh_term": [
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed diagnosis of MDS\n\n          -  Adequate liver and kidney function\n\n          -  Ineligible for, or refusing, allogeneic bone marrow transplant\n\n          -  At least 18 years of age\n\n          -  Discontinuation of growth factors (e.g., G- CSF) at least 2 weeks prior to study\n             entry\n\n        Exclusion Criteria:\n\n          -  Failure to recover from any prior surgery, or any major surgery within 4 weeks of\n             study entry\n\n          -  Pregnant or lactating women\n\n          -  History of allergy to eggs\n\n          -  Other investigational drugs within 14 days of study entry\n\n          -  Chemotherapy, radiotherapy or immunotherapy within 14 days of study entry\n\n          -  Concomitant steroids or hormones for the treatment of neoplasms"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "65", 
        "firstreceived_date": "May 6, 2002", 
        "id_info": {
            "nct_id": "NCT00035867", 
            "org_study_id": "TLK199.1001"
        }, 
        "intervention": {
            "intervention_name": "TLK199 HCl Liposomes for Injection", 
            "intervention_type": "Drug"
        }, 
        "lastchanged_date": "May 30, 2008", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294"
                    }, 
                    "name": "University of Alabama at Birmingham"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90404"
                    }, 
                    "name": "The Angeles Clinic & Research Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60637"
                    }, 
                    "name": "University of Chicago"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Skokie", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60077"
                    }, 
                    "name": "Midwest Cancer Research Group"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97239"
                    }, 
                    "name": "Oregon Health & Science University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "The Sarah Cannon Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75231"
                    }, 
                    "name": "Texas Cancer Associates"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "M.D. Anderson Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "University of Texas Health Science Center at San Antonio"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase 1-2a Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1/Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00035867"
        }, 
        "source": "Telik", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Telik", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2002", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2005"
    }, 
    "geocoordinates": {
        "M.D. Anderson Cancer Center": "29.76 -95.369", 
        "Midwest Cancer Research Group": "42.033 -87.733", 
        "Oregon Health & Science University": "45.523 -122.676", 
        "Texas Cancer Associates": "32.803 -96.77", 
        "The Angeles Clinic & Research Institute": "34.052 -118.244", 
        "The Sarah Cannon Cancer Center": "36.166 -86.784", 
        "University of Alabama at Birmingham": "33.521 -86.802", 
        "University of Chicago": "41.878 -87.63", 
        "University of Texas Health Science Center at San Antonio": "29.424 -98.494"
    }
}